Harrow (NASDAQ:HROW) & IM Cannabis (NASDAQ:IMCC) Head-To-Head Contrast

Harrow (NASDAQ:HROW) and IM Cannabis (NASDAQ:IMCC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Profitability

This table compares Harrow and IM Cannabis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harrow	-13.51%	-38.00%	-3.37%
IM Cannabis	-39.62%	N/A	-58.32%

Risk and Volatility

Harrow has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500.

Insider and Institutional Ownership

72.8% of Harrow shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 12.8% of Harrow shares are held by insiders. Comparatively, 5.9% of IM Cannabis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Harrow and IM Cannabis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1	2	7	0	2.60
IM Cannabis	1	0	0	0	1.00

Harrow currently has a consensus target price of $66.17, suggesting a potential upside of 123.70%. Given Harrow’s stronger consensus rating and higher possible upside, research analysts plainly believe Harrow is more favorable than IM Cannabis.

Earnings and Valuation

This table compares Harrow and IM Cannabis”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$275.59 million	4.02	-$5.14 million	($1.00)	-29.58
IM Cannabis	$45.80 million	0.01	-$8.10 million	($60.66)	-0.03

Harrow has higher revenue and earnings than IM Cannabis. Harrow is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Harrow beats IM Cannabis on 11 of the 14 factors compared between the two stocks.

About Harrow

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

About IM Cannabis

IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.